KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash from Financing Activities (2016 - 2025)

Pfizer (PFE) has disclosed Cash from Financing Activities for 17 consecutive years, with $596.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A to $596.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.3 billion through Dec 2025, changed N/A year-over-year, with the annual reading at -$10.3 billion for FY2025, 39.88% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $596.0 million at Pfizer, up from -$2.5 billion in the prior quarter.
  • The five-year high for Cash from Financing Activities was $27.2 billion in Q3 2023, with the low at -$12.0 billion in Q3 2024.
  • Average Cash from Financing Activities over 5 years is -$1.7 billion, with a median of -$2.8 billion recorded in 2021.
  • The sharpest move saw Cash from Financing Activities tumbled 256.23% in 2021, then skyrocketed 978.33% in 2023.
  • Over 5 years, Cash from Financing Activities stood at -$6.5 billion in 2021, then crashed by 51.88% to -$9.8 billion in 2022, then soared by 155.42% to $5.4 billion in 2023, then tumbled by 320.98% to -$12.0 billion in 2024, then surged by 104.96% to $596.0 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $596.0 million, -$2.5 billion, and -$3.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.